Get the Stockscreener App
1.23
2.38%
-0.03
Pre-market:
1.25
0.02
+1.63%
Dermata Therapeutics Inc stock is traded at $1.23, with a volume of 62,614.
It is down -2.38% in the last 24 hours and down -0.81% over the past month.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
See More
Previous Close:
$1.26
Open:
$1.28
24h Volume:
62,614
Relative Volume:
0.08
Market Cap:
$4.95M
Revenue:
-
Net Income/Loss:
$-7.56M
P/E Ratio:
-0.2332
EPS:
-5.274
Net Cash Flow:
$-7.76M
1W Performance:
+4.24%
1M Performance:
-0.81%
6M Performance:
-59.41%
1Y Performance:
-83.47%
1-Day Range:
$1.2201
$1.30
1-Week Range:
$1.15
$1.30
52-Week Range:
$1.10
$8.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.23 | 5.07M | 0 | -7.56M | -7.76M | -5.274 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan
DRMA Technical Analysis | Trend, Signals & Chart Patterns | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 as Trading Remains FlatGap Fill Strategy - Newser
Dermata shares rise after USPTO issues patent notice of allowance - MSN
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
DRMA Should I Buy - Intellectia AI
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
DRMA Stock Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dermata Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare - ChartMill
Intracoastal-linked holders report 4.99% stake in Dermata (NASDAQ: DRMA) - Stock Titan
Once-weekly Tome mask aims to bring professional skincare home by mid-2026 - Stock Titan
[10-Q] Dermata Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dermata (NASDAQ: DRMA) advances DTC pivot in Q1 2026 update - Stock Titan
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - newswire.com
TradingKey - TradingKey
What Dermata (DRMAW) flagged as biggest challenges ahead | DRMAW Q3 Earnings: Dermata Warrant Reports No Revenue or Earnings DataCommunity Sell Signals - Newser
Dermata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DRMAW Dermata quarterly earnings core metrics remain unavailable as investors await full official operational and financial disclosures.Forward Guidance - newser.com
DRMAW SEC FilingsDermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates Dermata Therapeutics stock at outperform By Investing.com - Investing.com South Africa
RBC Capital initiates Dermata Therapeutics stock at outperform - Investing.com
Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beatSurprise Factor - Cổng thông tin điện tử tỉnh Lào Cai
Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20Analyst Consensus - Cổng thông tin điện tử tỉnh Lào Cai
Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan
Patterns Watch: Does LogProstyle Inc have strong fundamentalsDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
Sentiment Watch: Will Dermata Therapeutics Inc Equity Warrant outperform the market in YEARWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
Are investors bearish on Dermata (DRMA) Stock | Price at $1.25, Up 2.87%Large Cap Trends - Xã Vĩnh Công
WSBCO Should I Buy - Intellectia AI
Bond Watch: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Moving Averages: Is Dermata Therapeutics Inc Equity Warrant gaining market share2026 Institutional & Verified Technical Signals - baoquankhu1.vn
Market Review: Will Dermata Therapeutics Inc benefit from AI trendsEntry Point & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Can Dermata (DRMA) Stock Go Higher | Price at $1.24, Up 2.07%Viral Trade Signals - Newser
Aug Sectors: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsTrade Exit Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Targets Report: Is Dermata Therapeutics Inc Equity Warrant stock undervalued right nowWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
What limits growth of Xeris (XERS) Stock | XERS Q4 Earnings: Beats Estimates by $0.02Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Gap Down: Will Bukit Jalil Global Acquisition 1 Ltd Equity Warrant benefit from green energy policies2026 Trends & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Whats the outlook for Dermata Therapeutics Incs sector2026 Price Targets & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
[PRE 14A] Dermata Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Market Moves: Can Dermata Therapeutics Inc Equity Warrant weather a recessionRate Hike & Smart Investment Allocation Insights - baoquankhu1.vn
Is Dermata (DRMA) Stock Losing Momentum | Price at $1.32, Up 2.33%Low Beta Factor - Newser
CAS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALYAF Should I Buy - Intellectia AI
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):